KNOWLEDGE BANK

Interviews

Interpharm Consultancy

Founder
Interpharm Consultancy has been providing advice about the UK generic market and consultancy services to generic manufacturers and distributors

Articles

3D Printing

The pharmaceutical industry is undergoing a profound transformation driven by advanced manufacturing technologies that challenge conventional models of drug development clinical supply and production Among these innovations threedimensional D printing and more specifically semisolid extrusion SSE printing is emerging as a highly promising approach for the manufacture of clinical batches

Research Insights

An Update On The Role Of Intestinal Cytochrome P450 Enzymes In Drug Disposition

Abstract Oral administration is the most commonly used route for drug treatment Intestinal cytochrome P CYPmediated metabolism can eliminate a large proportion of some orally administered drugs before they reach systemic circulation while leaving the passage of other drugs unimpeded A better understanding of the ability of intestinal P enzymes to me

Case Studies

Open Innovation in Pharmaceutical Industry: A Case Study by Eli Lilly

Abstract Interest on Open Innovation paradigm has seen a phenomenal increase since last two decades especially when Henry Chesbrough coined this term in triggering the creation of a new whole body of knowledge However all of his research work could not come up with a standardized allinone theory Instead we find a heterogeneous series of models tha

Techno Trends

New Method for Residual Solvent Characterization by GC-VUV

A new method has been announced by VUV Analytics for residual solvent testing in pharmaceutical products and excipients that significantly reduces analysis time while improving testing throughput It allows the combination of various sample types into a single test The gas chromatography Vacuum Ultraviolet GCVUV spectroscopy method reduces the GC separation time re...

White Papers

Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches

In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS

TOP ARTICLES

1

Artificial Intelligence in Oncology

Nancy Kapila

Nancy Kapila is a seasoned pharmaceutical consultant with over 5 years of varied experience and a Master’s in Pharmaceutics from Panjab University. She excels in drug mechanisms and interactions. Her career highlights include collaborating with numerous pharmaceutical companies and offering strategic insights and guidance. Nancy stands out for her dedication to keeping abreast of pharmaceutical advancements, regulatory changes, and emerging trends. She believes in continuous learning to navigate the industry’s complexities and provide innovative client solutions. Fascinated by the role of data analytics in decision-making, Nancy delves into data to uncover patterns and opportunities, offering evidence-based recommendations for process optimization, product development, and operational efficiency. Her career is driven by a relentless pursuit of knowledge, passion for data insights, and commitment to leading pharmaceutical companies towards success in a dynamic industry.

 

2

The Rapidly Evolving Landscape of Cancer Therapeutics

Rajesh Kumar

Rajesh Kumar is an Assistant Professor of Pharmaceutical Sciences at Kerala University of Health Sciences, India. He has been teaching Diploma, Bachelor, and Doctor of Pharmacy students for several years and is actively involved in research. He has authored more than 19 papers and is a reviewer for Bentham Science Publishers. His research includes applying the principles of pharmaceutical sciences, omics technologies, computational biology, and bioinformatics in the broad areas of cancer research, ethnopharmacology, drug delivery, targeting, and formulations.

 

Seetha Harilal

Seetha Harilal is an Assistant Professor of Pharmacology at Kerala University of Health Sciences, India. She has several years of experience in teaching Diploma, Bachelor, and Doctor of Pharmacy students and is actively pursuing research. She has authored more than 22 papers and is a manuscript reviewer for Bentham Science Publishers, Frontiers in Public Health, Frontiers in Medicine, and Archives of Medical Research (Elsevier). Her research includes the diverse areas of pharmacology and therapeutics, phytopharmaceuticals, cancer research, neurological disorders, and the application of omics technologies, computational pharmacology, and bioinformatics.

 

3

Incipient Biopharmaceutical Claims of Milk Derived Exosomes

Rakesh Kumar Tekade

Rakesh K. Tekade is a formulation researcher with of teaching and research experience. He has an explicit experience of over 10 years in teaching various modules for Ph.D, Masters & Bachelors students (@ Universities based in USA, UK, Malaysia, & India). He currently serving as Associate Professor at NIPER-Ahmedabad (An Institute of National Importance Government of India). Prior to this, Dr. Tekade was faculty at International Medical University, Kuala Lumpur, Malaysia. He took his postdoctoral trainings from UT Southwestern Medical Centre, Dallas, Texas, USA and University of Hawaii, Hilo, Hawaii, USA. He is a recipient of Commonwealth Fellowship at University of Central Lancashire, Preston, UK. Recently, Dr Tekade has been listed as Top 2% researcher in the field of Pharmacy and Pharmacology, by Stanford University, USA.

 

Nupur Vasdev

Nupur Vasdev is currently pursuing her PhD in the department of pharmaceutics from NIPER-Ahmedabad. She has completed M.S (Pharm.) in pharmaceutics from NIPER-Raebareli. She is currently working on targeted nano particulate drug delivery for obesity and cancer. Her research focus also includes surface modified exosome drug delivery for cancer and obesity.

 

Manisha Choudhary

Manisha Choudhary is currently pursuing her M.S. (Pharm) in Pharmaceutics at NIPER-Ahmedabad, India. She is currently working on aptamer decorated nanomaterials for improving the targeting. Her work majorly focuses on the improvement of the stability, targeting and robustness of aptamer conjugated nanomaterials for cancer treatment. Her work also focusses on the extraction of natural derived exosomes.

 

Suryanarayana Polaka

Suryanarayana Polaka is currently pursuing his PhD at NIPER-Ahmedabad, India. He is working in targeted drug delivery systems for the treatment of rheumatoid arthritis and wound healing. He also works on exosome mediated drug delivery. He co-authored 10 peer-reviewed publications in international journals, contributed > 7 international reference book chapters.

 

Kiran Kalia

Professor Kiran Kalia is a currently serving as Director and Professor at NIPER-Ahmedabad. Her work basically focused on the Proteomic markers for diabetic nephropathy, diabetic retinopathy and metal toxicity studies. Recently she started exploring the exosomes mediated drug delivery for delivering the genes for treating various ailments like cancer, wounds and diabetic nephropathy.

 

4

Advancing Automation and Digitalization in the Industrial Microbiology Workflow

Brad Grobler

Brad is Head of Biomonitoring Strategic Initiatives, which includes development and execution of  the Digital strategy in Robotics & Automation, eBusiness, Informatics and the Biomonitoring Ecosystem. Throughout his 10 years at the company, Brad has been engaged in Commercial, Operation and Strategy with regional and global focus.

 

5

Revolutionising Tuberculosis Treatment test

Ashok Aspatwar

Ashok Aspatwar, MS, PhD, is an Adjunct Professor at Tampere University, Finland. His research focuses on carbonic anhydrases in Mycobacterium tuberculosis persistence and anti-TB drug development, using molecular biology, medicinal chemistry, and AI-driven bioinformatics to explore novel therapeutic pathways and target mechanisms in TB.

Rarchita Sharma

Rarchita Sharma, M. Pharm, is a researcher at SVKM's Institute of Pharmacy, specialising in novel drug delivery for CNS disorders. She has published seven papers on topics like regulatory filings, AI in stroke care, and cardiovascular drugs, aiming to advance therapeutic innovations in pharmaceutical sciences.

press releasesRead more...

Enhertu approved in the EU as adjuvant treatment for patients with residual disease after neoadjuvant treatment for HER2-positive early breast cancer

AstraZeneca and Daiichi Sankyos Enhertu trastuzumab deruxtecan has been approved in the European Union EU as a monotherapy for the adjuvant treatment of adult patients with resected HERpositive breast cancer who have residual invasive disease after neoadjuvant taxanebased and HERtargeted treatment

Teva Acquires Worldwide Rights to BXCL501, Further Expanding Innovative Neuroscience Pipeline

Teva Pharmaceuticals International GmbH a subsidiary of Teva Pharmaceutical Industries Ltd today announced that it has completed the acquisition of assets from BioXcel Therapeutics Inc including worldwide rights to BXCL BXCL is an investigational dexmedetomidine

Ferring Pharmaceuticals and Gameto sign agreement for proposed acquisition

Ferring Pharmaceuticals and Gameto today announced that they have signed an agreement for a global transaction under which Ferring would acquire Gameto Completion remains subject to customary and other closing conditions Until closing the companies will continue to operate independently

Innovent Announces NMPA Acceptance of a New Indication Application of Sintilimab for the Treatment of Advanced Melanoma

Innovent Biologics Inc a worldclass biopharmaceutical company that develops manufactures and commercializes high quality medicines for the treatment of cancer metabolic autoimmune and other major diseases today announced that a New Indication Application for sintilimab in combination with Nolgileuce...

Georgiamune and Menarini Group Enter Exclusive Global License and Collaboration Agreement for GIM-621, a First-in-Class Oral Immuno-Oncology Agent

The Menarini Group Menarini a leading international pharmaceutical and diagnostics company and Stemline Therapeutics Inc Stemline a whollyowned subsidiary of the Menarini Group focused on bringing transformational oncology treatments to cancer patients along with Georgiamune Inc a clinicalstage biot...

Aptar Pharma Acquires Pulmotree, Expanding Growth Opportunities in Next-Generation Pulmonary Drug

Aptar Pharma a global leader in drug delivery dosing protection technologies and services today announced the strategic acquisition of PULMOTREE a Munich Germanybased life science company specializing in pulmonary drug delivery systems for targeted delivery to the lungs The acquisition is expected t...

EventsRead more...

26 - 28

Oct 2026

ACHEMA Middle East 2026

RICEC, Riyadh, KSA, Saudi Arab...

26 - 28

Oct 2026

World Orphan Drug Congress

RAI, Amsterdam, Netherlands

27 - 28

Oct 2026

PM& AC 2026

Novotel Hyderabad Convention C...

28 - 30

Oct 2026

02 - 04

Nov 2026

Pharma Forum EMEA 2026

Dom Pedro Lisboa Hotel, Lisbon...

02 - 04

Nov 2026

Cancer R&D 2026

Houston, TX, USA

03 - 05

Nov 2026

10th Dermatology Drug Development

Boston, Massachusetts at The C...

03 - 04

Nov 2026

PDA Aseptic Processing of Biopharma Conference

Sheraton Grand Incheon Hotel,...

LATEST NEWSRead more...

Astellas Enters into Agreement with Audax for Immuno-Oncology Candidate DAX-044

Astellas Pharma and Audax Biosciences have entered into an exclusive option and licence agreement for DAX an investigational antibodycytokine fusion being developed for cancer immunotherapy DAX is designed to deliver interleukin IL an immuneactivating protein more selectively to the tumour microenvi...

Sumitomo Pharma’s Enzomenib Receives Breakthrough Therapy Designation for Relapsed or Refractory KMT2A-Rearranged Acute Leukaemia

Sumitomo Pharma America has announced that the US Food and Drug Administration FDA has granted Breakthrough Therapy designation to enzomenib DSP for treating patients with relapsed or refractory acute leukaemia carrying a KMTA gene rearrangement

Pfizer’s TALZENNA Plus XTANDI Approved for Earlier Treatment of Metastatic Prostate Cancer

Pfizer has received approval from the US Food and Drug Administration FDA to expand the use of TALZENNA talazoparib in combination with XTANDI enzalutamide for men with metastatic prostate cancer that is sensitive to hormone treatment and has specific homologous recombination repair HRR gene mutatio...

Okomera Signs Agreement with Servier for Cancer Research Technology

Okomera has signed a commercial agreement with Servier to support the development of new cancer treatments using its tumour miniaturisation technology More than of oncology drug candidates fail to reach the market making it important to identify promising treatments at an early stage Okomeras platf...

AstraZeneca and Oracle Launch Global AI Collaboration to Optimise Clinical Trials

AstraZeneca and Oracle Health and Life Sciences have launched a global collaboration to use artificial intelligence AI realworld data and cloud technology to improve clinical trial efficiency and patient outcomes The collaboration will combine AstraZenecas expertise in drug development clinical rese...

UCB Receives Approval for ZILBRYSQ Autoinjector for Adults with Generalised Myasthenia Gravis

UCB has received approval from the US Food and Drug Administration FDA for a new autoinjector option for ZILBRYSQ zilucoplan a treatment for adults with generalised myasthenia gravis gMG who test positive for antiacetylcholine receptor AChR antibodies